According to Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology, AR-V7 expression on CTCs can help CRPC patients treated with abiraterone/enzalutamide make decisions about their next course of treatment.529 In terms of CTCs phenotype, Lindsay et al. demonstrated that Ki67 and vimentin expression in CTCs correlates with poor prognosis in mCRPC.530 Second, plasma ctDNA was found to be a potential clinical marker for the early detection of prostate cancer, and its concentration can come to differentiate between malignant disease and benign hyperplasia of the prostate. The gene discussed is MKI67; the disease is prostate carcinoma.